FY2024 Earnings Forecast for MRSN Issued By William Blair

Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at William Blair issued their FY2024 EPS estimates for shares of Mersana Therapeutics in a research note issued to investors on Wednesday, February 5th. William Blair analyst A. Hsieh forecasts that the company will post earnings of ($0.68) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Mersana Therapeutics' current full-year earnings is ($0.61) per share. William Blair also issued estimates for Mersana Therapeutics' FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($1.29) EPS.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. The business had revenue of $12.60 million during the quarter, compared to analyst estimates of $7.53 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. Mersana Therapeutics's quarterly revenue was up 63.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.35) EPS.

A number of other analysts have also commented on the stock. Citigroup began coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They set a "buy" rating and a $5.00 price target for the company. Wedbush restated an "outperform" rating and set a $4.00 price target (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday, January 10th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Mersana Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $5.57.

Mersana Therapeutics Stock Down 5.6 %

MRSN stock traded down $0.04 during midday trading on Monday, reaching $0.61. 3,585,750 shares of the company's stock traded hands, compared to its average volume of 8,266,707. The company has a market cap of $75.27 million, a price-to-earnings ratio of -1.00 and a beta of 1.39. The firm's fifty day moving average price is $1.19 and its 200-day moving average price is $1.65. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 52 week low of $0.49 and a 52 week high of $6.28.

Institutional Investors Weigh In On Mersana Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC grew its position in Mersana Therapeutics by 95.8% during the third quarter. Exchange Traded Concepts LLC now owns 85,006 shares of the company's stock valued at $161,000 after acquiring an additional 41,586 shares during the last quarter. US Bancorp DE bought a new position in shares of Mersana Therapeutics in the third quarter worth approximately $31,000. Los Angeles Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 8.1% in the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company's stock worth $358,000 after purchasing an additional 14,240 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Mersana Therapeutics by 368.9% in the third quarter. GSA Capital Partners LLP now owns 271,774 shares of the company's stock worth $514,000 after purchasing an additional 213,814 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Mersana Therapeutics in the third quarter worth approximately $52,000. 93.92% of the stock is owned by hedge funds and other institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.